Back to Atlas
APotentially durableStandard research/education caution
CMP-0057
Investigational
Garetosmab
Ergogenic / Myostatin-Activin
Lean-mass preservation and potential muscle remodeling via activin blockade
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Monoclonal antibody
- Primary mechanism
- Activin A neutralization
- Primary market use
- Muscle preservation / obesity combination
Pharmacology
- Molecular weight (Da)
- ~150,000
- Oral bioavailability
- N/A
- Half-life
- ~2-4 wk
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- Clinical
- Clinical status
- Investigational
- Value-for-money score
- 3 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Often discussed with trevogrumab for GLP-1-associated lean-mass preservation